Thrivent Financial for Lutherans
TPTX

Thrivent Financial for Lutherans’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Thrivent Financial for Lutherans’s Portfolio TPTX Stock Details TPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-64,286
Closed -$1.73M – 2563
2022
Q1 		$1.73M Hold
64,286
– – ﹤0.01% 1427
2021
Q4 		$3.07M Buy
+64,286
New +$2.87M 0.01% 1127

Other funds holding TPTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Thrivent Financial for Lutherans's TPTX Position: Q2 2022 in Review

Thrivent Financial for Lutherans sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q2 2022, closing a stake of 64,286 shares — an estimated $1.73M sold.

Thrivent Financial for Lutherans first reported a position in TPTX in Q4 2021 and held it in 2 quarters. The position peaked at $3.07M in Q4 2021. 208 funds tracked by Wall St. Rank hold TPTX as of Q2 2022.

  • Thrivent Financial for Lutherans reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Thrivent Financial for Lutherans sold 64,286 Turning Point Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $1.73M.
  • Thrivent Financial for Lutherans first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q4 2021 and held it in 2 quarters.
  • Thrivent Financial for Lutherans's Turning Point Therapeutics, Inc. Common Stock position peaked at $3.07M in Q4 2021.
  • 208 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Thrivent Financial for Lutherans's 13F filing for Q2 2022, filed 16 Aug 2022.